FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?

Episode 69:DUPLEX Sparsentan, it’s no Acthar Gel

Twice monthly (aspirational) recap of the NephJC journal club. NephJC reviews the most important manuscripts which are driving nephrology forward and improving our understanding of the kidney.

Medicine

Science & Medicine

Science

Health & Fitness

Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something.

No. The answer is no.

But honestly we have all been guilted into ordering some clonidine or god forbid some IV hydralazine.

Stop it. Just stop it.

Join the filtrate as we dissect a recent study looking at this issue with the lead author.

Freely Filtered 68: Inpatient hypertension

NephMadness prides itself on not repeating topics. Most topics don’t get revisited for years after a single appearance. But one region stands alone. One region is making its fourth appearance in the 12 year history of NephMadness! That region is Animal House!

Modern medical education doesn’t go to the comparative physiology well very often. So when we do, it is always fresh and exciting. Join the Filtrate as we explore the fascinating world of the Gila Monster and Mourning Dove.

Freely Filtered 67: NephMadness and Animal House

So this one has been on the hard drive gathering dust for quite awhile. There were significant technical problems (in other words, Joel screwed up. But the episode is now complete and despite some obvious stutters, it turned out pretty good.)

Freely Filtered 66: NephJC Summer Book Club

The fluids wars have been going back and forth and now have another big win. This time in transplant.

Episode 69:DUPLEX Sparsentan, it’s no Acthar Gel

Download our free app to listen on your phone